← back to search

Daniel K. Benjamin

Duke University · US
Area of research
Public Health, Environmental and Occupational Health · Infectious Diseases
Research interest
Research interests include Neonatal and Maternal Infections, Antifungal resistance and susceptibility, Pharmaceutical studies and practices, and Antibiotics Pharmacokinetics and Efficacy.
h-index
86
citations
28,399
works
540
NIH funding
primary concept
email

Recent publications

Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity.
2026cited by 0position: contributordoi
Pregnancy and Fetal Outcomes Following Prenatal Exposure to Modafinil and/or Armodafinil: A 14-Year Registry Study.
2025cited by 0position: contributordoi
Acyclovir Dosing Practices Across a Multicenter Cohort of Neonatal Intensive Care Units.
2024cited by 0position: contributordoi
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
JAMA 2023cited by 67position: middledoi
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials
JAMA Network Open 2023cited by 17position: middledoi
Utilization and Impact of Symptomatic and Exposure SARS-CoV-2 Testing in K-12 Schools
PEDIATRICS 2023cited by 6position: middledoi
School Masking Policies and Secondary SARS-CoV-2 Transmission
PEDIATRICS 2022cited by 53position: middledoi
Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.
2022cited by 1position: contributordoi
Disparities in Risks of Inadequate and Excessive Intake of Micronutrients during Pregnancy
Journal of Nutrition 2021cited by 43position: middledoi
Harmonising regulatory approval for antibiotics in children
The Lancet Child & Adolescent Health 2021cited by 24position: middledoi
Physiologically‐Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants
CPT Pharmacometrics & Systems Pharmacology 2019cited by 25position: middledoi
Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis
Antimicrobial Agents and Chemotherapy 2019cited by 17position: middledoi
A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network
Journal of Clinical and Translational Science 2018cited by 39position: middledoi
Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative
Contemporary Clinical Trials Communications 2017cited by 96position: lastdoi
The Need for Pediatric Drug Development
The Journal of Pediatrics 2017cited by 80position: middledoi
External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models
Antimicrobial Agents and Chemotherapy 2017cited by 19position: middledoi
Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates
Pediatric Research 2016cited by 107position: middledoi
Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units
PEDIATRICS 2014cited by 161position: middledoi
Effect of Fluconazole Prophylaxis on Candidiasis and Mortality in Premature Infants
JAMA 2014cited by 140position: firstdoi
Developmental Pharmacokinetics of Piperacillin and Tazobactam Using Plasma and Dried Blood Spots from Infants
Antimicrobial Agents and Chemotherapy 2014cited by 72position: middledoi
Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design
Antimicrobial Agents and Chemotherapy 2014cited by 71position: middledoi
Use of Opportunistic Clinical Data and a Population Pharmacokinetic Model to Support Dosing of Clindamycin for Premature Infants to Adolescents
Clinical Pharmacology & Therapeutics 2014cited by 69position: middledoi
10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Clinical Infectious Diseases 2013cited by 694position: middledoi
Medication Use in the Neonatal Intensive Care Unit
American Journal of Perinatology 2013cited by 321position: middledoi
Neurodevelopmental Outcome of Extremely Low Birth Weight Infants with Candida Infection
The Journal of Pediatrics 2013cited by 121position: lastdoi
Early Sepsis Does Not Increase the Risk of Late Sepsis in Very Low Birth Weight Neonates
The Journal of Pediatrics 2013cited by 35position: middledoi
Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates
The Pediatric Infectious Disease Journal 2012cited by 177position: middledoi
Safety and Effectiveness of Meropenem in Infants With Suspected or Complicated Intra-abdominal Infections
Clinical Infectious Diseases 2012cited by 67position: middledoi
Empiric Antifungal Therapy and Outcomes in Extremely Low Birth Weight Infants with Invasive Candidiasis
The Journal of Pediatrics 2012cited by 66position: middledoi
Therapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age
The Pediatric Infectious Disease Journal 2012cited by 45position: middledoi

Grants

Duke-Utah HEAL KIDS Pain Resource and Data Center
NIH1U24HD116261-01$724,9812024–2030PIRePORTER
Duke-Utah HEAL KIDS Pain Resource and Data Center
NIH5U24HD116261-02$677,8692024–2030PIRePORTER
National Career Development Program for Researchers in Pediatric Clinical Pharmacology
NIH7K12HD113189-02$294,1442024–2028PIRePORTER
National Career Development Program for Researchers in Pediatric Clinical Pharmacology
NIH5K12HD113189-04$292,1942024–2028PIRePORTER
National Career Development Program for Researchers in Pediatric Clinical Pharmacology
NIH5K12HD113189-03$292,1942024–2028PIRePORTER
BPCA INNOVATIVE TRIAL DESIGNS AND ASSAY DEVELOPMENTS IN PEDIATRIC THERAPEUTICS
NIH275201800003I-0-759402300004-1$3,699,8612023–2026Contact PIRePORTER
National Career Development Program for Researchers in Pediatric Clinical Pharmacology
NIH1K12HD113189-01$12023–2023PIRePORTER
ACTIV-6
NIH3U24TR001608-07S1$20,600,0002022–2025Contact PIRePORTER
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
NIH5U24TR004314-03$3,323,2782022–2027Contact PIRePORTER
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
NIH5U24TR004314-04$2,758,8762022–2027Contact PIRePORTER
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
NIH5U24TR004314-02$2,475,0312022–2027Contact PIRePORTER
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
NIH3U24TR004314-02S1$1,534,4972022–2027Contact PIRePORTER
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
NIH1U24TR004314-01$669,8632022–2027Contact PIRePORTER
Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)
NIH3U24TR001608-07S2$12022–2023Contact PIRePORTER
ACTIV-6
NIH3U24TR001608-06S1$77,049,2002021–2025Contact PIRePORTER
ACTIV 6
NIH3U24TR001608-05S4$38,494,5992021–2023Contact PIRePORTER
SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools
NIH1OT2HD107559-01$3,004,5262021–2024PIRePORTER
SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools
NIH3OT2HD107559-01S1$1,995,4752021–2024PIRePORTER
ECHO Coordinating Center Administration Core
NIH5U2COD023375-04$396,1712019–Contact PIRePORTER
ECHO Coordinating Center Administration Core
NIH5U2COD023375-03$1,480,7852018–Contact PIRePORTER
Global Pediatric Clinical Trials Network
NIH5U18FD006298-03$1,000,0002017–2022Contact PIRePORTER
Global Pediatric Clinical Trials Network
NIH5U18FD006298-02$1,000,0002017–2022Contact PIRePORTER
Global Pediatric Clinical Trials Network
NIH3U18FD006298-04S1$500,0002017–2022Contact PIRePORTER
ECHO Coordinating Center
NIH5U2COD023375-06$17,502,8572016–2023Contact PIRePORTER
ECHO Coordinating Center
NIH5U2COD023375-05$14,970,7072016–2023PIRePORTER

Frequent collaborators

Michael Cohen‐Wolkowiez · Indiana University School of Medicine6 papers (2012–2019)P. Brian Smith · University of Iowa5 papers (2013–2019) · 4 papers (2022–2026)Edmund V. Capparelli · University of California San Diego4 papers (2014–2017)Christoph P. Hornik · National Institute of Allergy and Infectious Diseases3 papers (2013–2019)Brenda B. Poindexter · University of Alabama3 papers (2014–2014)John S. Bradley · Rady Children's Hospital-San Diego3 papers (2013–2021)Matthew M. Laughon · University of North Carolina at Chapel Hill3 papers (2013–2014)Kevin Watt · University of Utah3 papers (2014–2019)Kelly C. Wade · Medical College of Wisconsin3 papers (2014–2019)Robert M. Ward · University of Utah3 papers (2012–2017)Daniel González · University of Florida3 papers (2014–2019)Shahnaz Duara · Colorado Kidney Care3 papers (2014–2019)M. Alan Brookhart · Amgen (United States)2 papers (2022–2023)Reese H. Clark · University of Alabama at Birmingham2 papers (2013–2014)Karen E. Shattuck · The University of Texas Medical Branch at Galveston2 papers (2014–2019) · 2 papers (2014–2014)Christoph P. Hornik · Duke University2 papers (2022–2024)Chi Hornik · Duke University2 papers (2022–2026)Jennifer E. Schuster · Children's Mercy Hospital2 papers (2022–2023)